Standard

A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting. / Geelhoed, W. J.; Damanik, F. F.R.; Hamming, J. F.; van Agen, M. S.; de Boer, H. C.; Restrepo, M. Tobón; Kislaya, A.; Poelma, C.; van Zonneveld, A. J.; More Authors.

In: Biomaterials, Vol. 229, 119577, 2020.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Geelhoed, WJ, Damanik, FFR, Hamming, JF, van Agen, MS, de Boer, HC, Restrepo, MT, Kislaya, A, Poelma, C, van Zonneveld, AJ & More Authors 2020, 'A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting', Biomaterials, vol. 229, 119577. https://doi.org/10.1016/j.biomaterials.2019.119577

APA

Geelhoed, W. J., Damanik, F. F. R., Hamming, J. F., van Agen, M. S., de Boer, H. C., Restrepo, M. T., Kislaya, A., Poelma, C., van Zonneveld, A. J., & More Authors (2020). A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting. Biomaterials, 229, [119577]. https://doi.org/10.1016/j.biomaterials.2019.119577

Vancouver

Author

Geelhoed, W. J. ; Damanik, F. F.R. ; Hamming, J. F. ; van Agen, M. S. ; de Boer, H. C. ; Restrepo, M. Tobón ; Kislaya, A. ; Poelma, C. ; van Zonneveld, A. J. ; More Authors. / A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting. In: Biomaterials. 2020 ; Vol. 229.

BibTeX

@article{4185cad1f8734aa6a6b3b5f50066e952,
title = "A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting",
abstract = "The durability of prosthetic arteriovenous (AV) grafts for hemodialysis access is low, predominantly due to stenotic lesions in the venous outflow tract and infectious complications. Tissue engineered blood vessels (TEBVs) might offer a tailor-made autologous alternative for prosthetic grafts. We have designed a method in which TEBVs are grown in vivo, by utilizing the foreign body response to subcutaneously implanted polymeric rods in goats, resulting in the formation of an autologous fibrocellular tissue capsule (TC). One month after implantation, the polymeric rod is extracted, whereupon TCs (length 6 cm, diameter 6.8 mm) were grafted as arteriovenous conduit between the carotid artery and jugular vein of the same goats. At time of grafting, the TCs were shown to have sufficient mechanical strength in terms of bursting pressure (2382 ± 129 mmHg), and suture retention strength (SRS: 1.97 ± 0.49 N). The AV grafts were harvested at 1 or 2 months after grafting. In an ex vivo whole blood perfusion system, the lumen of the vascular grafts was shown to be less thrombogenic compared to the initial TCs and ePTFE grafts. At 8 weeks after grafting, the entire graft was covered with an endothelial layer and abundant elastin expression was present throughout the graft. Patency at 1 and 2 months was comparable with ePTFE AV-grafts. In conclusion, we demonstrate the remodeling capacity of cellularized in vivo engineered TEBVs, and their potential as autologous alternative for prosthetic vascular grafts.",
author = "Geelhoed, {W. J.} and Damanik, {F. F.R.} and Hamming, {J. F.} and {van Agen}, {M. S.} and {de Boer}, {H. C.} and Restrepo, {M. Tob{\'o}n} and A. Kislaya and C. Poelma and {van Zonneveld}, {A. J.} and {More Authors}",
note = "Green Open Access added to TU Delft Institutional Repository {\textquoteleft}You share, we take care!{\textquoteright} – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.",
year = "2020",
doi = "10.1016/j.biomaterials.2019.119577",
language = "English",
volume = "229",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting

AU - Geelhoed, W. J.

AU - Damanik, F. F.R.

AU - Hamming, J. F.

AU - van Agen, M. S.

AU - de Boer, H. C.

AU - Restrepo, M. Tobón

AU - Kislaya, A.

AU - Poelma, C.

AU - van Zonneveld, A. J.

AU - More Authors, null

N1 - Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.

PY - 2020

Y1 - 2020

N2 - The durability of prosthetic arteriovenous (AV) grafts for hemodialysis access is low, predominantly due to stenotic lesions in the venous outflow tract and infectious complications. Tissue engineered blood vessels (TEBVs) might offer a tailor-made autologous alternative for prosthetic grafts. We have designed a method in which TEBVs are grown in vivo, by utilizing the foreign body response to subcutaneously implanted polymeric rods in goats, resulting in the formation of an autologous fibrocellular tissue capsule (TC). One month after implantation, the polymeric rod is extracted, whereupon TCs (length 6 cm, diameter 6.8 mm) were grafted as arteriovenous conduit between the carotid artery and jugular vein of the same goats. At time of grafting, the TCs were shown to have sufficient mechanical strength in terms of bursting pressure (2382 ± 129 mmHg), and suture retention strength (SRS: 1.97 ± 0.49 N). The AV grafts were harvested at 1 or 2 months after grafting. In an ex vivo whole blood perfusion system, the lumen of the vascular grafts was shown to be less thrombogenic compared to the initial TCs and ePTFE grafts. At 8 weeks after grafting, the entire graft was covered with an endothelial layer and abundant elastin expression was present throughout the graft. Patency at 1 and 2 months was comparable with ePTFE AV-grafts. In conclusion, we demonstrate the remodeling capacity of cellularized in vivo engineered TEBVs, and their potential as autologous alternative for prosthetic vascular grafts.

AB - The durability of prosthetic arteriovenous (AV) grafts for hemodialysis access is low, predominantly due to stenotic lesions in the venous outflow tract and infectious complications. Tissue engineered blood vessels (TEBVs) might offer a tailor-made autologous alternative for prosthetic grafts. We have designed a method in which TEBVs are grown in vivo, by utilizing the foreign body response to subcutaneously implanted polymeric rods in goats, resulting in the formation of an autologous fibrocellular tissue capsule (TC). One month after implantation, the polymeric rod is extracted, whereupon TCs (length 6 cm, diameter 6.8 mm) were grafted as arteriovenous conduit between the carotid artery and jugular vein of the same goats. At time of grafting, the TCs were shown to have sufficient mechanical strength in terms of bursting pressure (2382 ± 129 mmHg), and suture retention strength (SRS: 1.97 ± 0.49 N). The AV grafts were harvested at 1 or 2 months after grafting. In an ex vivo whole blood perfusion system, the lumen of the vascular grafts was shown to be less thrombogenic compared to the initial TCs and ePTFE grafts. At 8 weeks after grafting, the entire graft was covered with an endothelial layer and abundant elastin expression was present throughout the graft. Patency at 1 and 2 months was comparable with ePTFE AV-grafts. In conclusion, we demonstrate the remodeling capacity of cellularized in vivo engineered TEBVs, and their potential as autologous alternative for prosthetic vascular grafts.

UR - http://www.scopus.com/inward/record.url?scp=85074348718&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2019.119577

DO - 10.1016/j.biomaterials.2019.119577

M3 - Article

C2 - 31704466

AN - SCOPUS:85074348718

VL - 229

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

M1 - 119577

ER -

ID: 68569878